CD274 and non-small cell lung carcinoma: Like BIRCH, FIR was a phase II, single-arm study that administered atezolizumab as first (cohort 1), second (cohort 2), and third-line (cohort 3) therapy in NSCLC among patients with a minimum PDL-1 expression of 5% (TC2/3 or IC2/3).